Biogen’s next Alzheimer drug feeds push for FDA approval revamp

Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway.

・ From Bloomberg